GGrantIndex
← Leaderboards

Alexei G Basnakian

Central Arkansas Veterans Hlthcare Sys

$3,611,011
Attributed
$3,611,011
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $596.7K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,611,011 · 6
VA$0 · 3

By mechanism

R01$1,499,048 · 1
P20$1,027,993 · 1
P30$596,700 · 1
R21$362,750 · 1
R03$124,520 · 1
P01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Central Arkansas Veterans Hlthcare Sys

Same institution · by research overlap

Others in their field

Top investigators on “Injury

Research focus

InjuryCell InjuryKidneyDna FragmentationCell DeathIn VitroAffectDeoxyribonuclease IMediatingIn VivoCellsAcuteTubular FormationEndonucleaseEnzymesApoptoticAcute Renal Failure With Renal Papillary NecrosisDeoxyribonucleasesPharmaceutical PreparationsReportingEpitheliumEndonuclease GKidney CellEpithelial Cells

Grant awards (33)

Admin Core$596,700
P30 · FY2025 · GM · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Nuclease mechanisms in acute kidney injury$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Cellular and Molecular Toxicology Core$258,400
P20 · FY2023 · GM · contact PI
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis$0
I01 · FY2023 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Cellular and Molecular Toxicology Core$252,793
P20 · FY2022 · GM · contact PI
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis$0
I01 · FY2022 · VA · contact PI
Cellular and Molecular Toxicology Core$258,400
P20 · FY2021 · GM · contact PI
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis$0
I01 · FY2021 · VA · contact PI
Cellular and Molecular Toxicology Core$258,400
P20 · FY2020 · GM · contact PI
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis$0
I01 · FY2020 · VA · contact PI
New mechanistic therapies for myoglobinuric acute kidney injury$0
I01 · FY2018 · VA · contact PI
New mechanistic therapies for myoglobinuric acute kidney injury$0
I01 · FY2017 · VA · contact PI
New mechanistic therapies for myoglobinuric acute kidney injury$0
I01 · FY2016 · VA · contact PI
New mechanistic therapies for myoglobinuric acute kidney injury$0
I01 · FY2015 · VA · contact PI
Novel endonuclease-targeted approaches to nephroprotection$0
I01 · FY2013 · VA · contact PI
Premortem enzymatic DNA damage in kidney injury$284,229
R01 · FY2012 · DK · contact PI
Novel endonuclease-targeted approaches to nephroprotection$0
I01 · FY2012 · VA · contact PI
Premortem enzymatic DNA damage in kidney injury$284,229
R01 · FY2011 · DK · contact PI
Novel endonuclease-targeted approaches to nephroprotection$0
I01 · FY2011 · VA · contact PI
Premortem enzymatic DNA damage in kidney injury$287,100
R01 · FY2010 · DK · contact PI
Premortem enzymatic DNA damage in kidney injury$63,990
R01 · FY2010 · DK · contact PI
Premortem enzymatic DNA damage in kidney injury$290,000
R01 · FY2009 · DK · contact PI
LDL isoforms in kidney-related atherosclerosisv$156,500
R21 · FY2009 · HL · contact PI
Novel endonuclease-targeted approaches to nephroprotection$0
I01 · FY2009 · VA · contact PI
Premortem enzymatic DNA damage in kidney injury$289,500
R01 · FY2008 · DK · contact PI
LDL isoforms in kidney-related atherosclerosisv$206,250
R21 · FY2008 · HL · contact PI
Endonuclease dificiency in breast cancer progression$61,520
R03 · FY2006 · CA · contact PI
Endonuclease deficiency in breast cancer progression$63,000
R03 · FY2005 · CA
Regulation of DNase I During Ischemic Renal Injury$0
P01 · FY2002 · DK
Regulation of DNase I During Ischemic Renal Injury$0
P01 · FY2001 · DK